Changes in multiple myeloma epidemiology in the last thirty years: a single centre experience.
In this study we have evaluated 772 multiple myeloma (MM) patients for clinical presentation, response to treatment, relapse modality, and survival in the last 30 years. Patients were divided, according to the date of diagnosis in group I or group II (before and after 1994, respectively) and therapy (high or conventional dose). Bone pain and early deaths were statistically reduced in group II, whereas MM that evolved from monoclonal gammopathy of undetermined significance (MGUS) had increased. The efficacy of high dose therapy (HDT) over conventional dose therapy (CDT) was confirmed through analysis of response rate, progression free, and overall survival. Relapse modality was similar after HDT or CDT. Among older patients, those diagnosed after 1994 lived longer than those diagnosed before 1994. In the last 30 years, the clinical presentation of multiple myeloma remained substantially unchanged. The new therapeutic approaches, chemotherapy and supportive therapy, allowed better control of the disease with an improvement of survival.
Zappasodi
Patrizia
P
Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Viale Golgi 19, 27100 Pavia, Italy. p.zappasodi@smatteo.pv.it
Corso
Alessandro
A
Klersy
Catherine
C
Pica
Gianmatteo
G
Mangiacavalli
Silvia
S
Varettoni
Marzia
M
Rusconi
Chiara
C
Pascutto
Cristiana
C
Lazzarino
Mario
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000401:mortality*; D009364:Neoplasm Recurrence, Local / Q000401:mortality; D009367:Neoplasm Staging / Q000379:methods; D016019:Survival Analysis
D000970:Antineoplastic Agents